Empowering IVF success through data-driven embryo insights
CellKinetica identifies embryos with the highest implantation potential using genomic biomarkers already produced during IVF + PGT-A. Fewer transfers, shorter treatment cycles, and a faster path to pregnancy.
Fewer transfers
from better selection
Time to pregnancy
Faster
less cycles
Clinic-ready
ISO mindset
audit-friendly
Training scale
embryo genomes analyzed
Signal discovery
implantation success markers
Clinical validation
live-birth pregnancies
Signals come from our prototype and validation datasets; transparent to support clinician judgment—no black-box outputs.
What we do
CellKinetica combines genomic biomarkers with clinical context to prioritize embryos most likely to implant. We operate inside the existing IVF + PGT-A workflow—no extra testing or lab steps—and return clear, auditable guidance for clinicians and patients.
- Objective, reproducible scoring reduces guesswork and bias.
- Fewer failed transfers lower emotional and financial burden.
- Faster readouts accelerate time-to-transfer and time-to-pregnancy.
Objective embryo scoring
Genomic biomarkers identify embryos with the highest implantation potential without extra procedures.
No workflow disruption
Fits directly into the standard IVF + PGT-A pipeline. No added lab time or consumables.
Actionable in days
Clinics receive clear prioritization guidance fast, accelerating transfer decisions.
Why it matters
IVF success rates remain below 40%. Each failed transfer costs time, budget, and hope. By strengthening embryo selection with genomic evidence, CellKinetica helps clinics cut cycles and get patients to a positive pregnancy sooner.
How it works
Designed for auditability and clinical workflows.
1) Ingest existing data
We use genomic data produced during PGT-A. No new sampling, no new instruments.
2) Score viability
Our pipeline identifies biomarkers tied to implantation potential and prioritizes embryos accordingly.
3) Deliver decisions
Clinically useful guidance arrives quickly, with clear confidence indicators for each embryo.
Product snapshots
Official assets to keep the experience faithful to the brand.
Functional prototype
Live scoring flow with clinic-friendly readouts.
Goal
Reduce failed transfers with objective embryo prioritization.
Validation
Data-driven validation plan aligned to clinical workflows.
Proof points
Built with embryologists, geneticists, and clinical operators to ensure reliability, transparency, and real-world fit.
- Improved prioritization reduces failed transfers and emotional toll.
- Data-driven scoring supports clinician judgment with transparent signals.
- Designed alongside embryologists for adoption without retraining.
Security & privacy
Defense-in-depth for PHI and genomic data.
Clinical partnership
Co-developed with clinic teams.
Leadership
Founders with deep genomics, clinical, and scalable infrastructure expertise.
.87cd1e62.svg)
Konstantin Popadin, PhD
Full time CEO (Switzerland)
Geneticist at Lomonosov MSU, Harvard, EPFL. Successfully managed teams of 50+ researchers.
.2507dbf2.svg)
Eugenii Tretiakov, PhD
Full time CTO (Austria)
Developmental Biologist & Bio/Data/DevOps Engineer. 8+ years building HPC clusters & computational pipelines. Technical leader bridging wet-lab biology & scalable cloud infrastructure.
Let’s talk
Tell us about your clinic workflow or research program. We respond within two business days and only use your email for follow-up.